肠道菌群
失调
2型糖尿病
代谢组
胰岛素抵抗
生物
2型糖尿病
粪便细菌疗法
代谢组学
医学
糖尿病
生物信息学
免疫学
微生物学
内分泌学
抗生素
艰难梭菌
作者
Jiasheng Wu,Kang-Ping Yang,Hancheng Fan,Meilin Wei,Qin Xiong
标识
DOI:10.3389/fendo.2023.1114424
摘要
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia and insulin resistance. The incidence of T2DM is increasing globally, and a growing body of evidence suggests that gut microbiota dysbiosis may contribute to the development of this disease. Gut microbiota-derived metabolites, including bile acids, lipopolysaccharide, trimethylamine-N-oxide, tryptophan and indole derivatives, and short-chain fatty acids, have been shown to be involved in the pathogenesis of T2DM, playing a key role in the host-microbe crosstalk. This review aims to summarize the molecular links between gut microbiota-derived metabolites and the pathogenesis of T2DM. Additionally, we review the potential therapy and treatments for T2DM using probiotics, prebiotics, fecal microbiota transplantation and other methods to modulate gut microbiota and its metabolites. Clinical trials investigating the role of gut microbiota and its metabolites have been critically discussed. This review highlights that targeting the gut microbiota and its metabolites could be a potential therapeutic strategy for the prevention and treatment of T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI